Latest Conference Coverage

Investigating IMU-838 for Relapsing MS

Robert Fox, MD, Vice-Chair for Research at the Cleveland Clinic Neurological Institute, discussed the findings of the phase 2 EMPhASIS trial of this investigational MS therapy.

Advantages of Sublingual Apomorphine in Parkinson Disease: Jennifer S. Hui, MD

The assistant professor of neurology at the Keck School of Medicine at University of Southern California shared her insight into the study data and the therapy’s potential advantages for patients with Parkinson disease.

Factors That Influence Practice Effects: Stephen Rao, PhD, ABPP-Cn

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed populations that exhibit greater practice effects than others.

Improving Device-Aided Therapy Screening in Parkinson Disease: Hubert Fernandez, MD

The director of the Center for Neurological Restoration at Cleveland Clinic discussed why gaps remain in screening for patients with Parkinson disease who may be eligible for device-aided therapies.

Atogepant’s Impact on Migraine Reductions and Patient-Reported Outcomes

Lawrence Severt, MD, PhD, discussed the results from the phase 3 ADVANCE trial of atogepant, and its effect on a number of patient-reported outcomes.

Developing Accessible Neurotechnology: Richard Gershon, PhD

The vice chair for research at the Northwestern University Feinberg School of Medicine discussed creating a mobile cognitive toolbox to be used by all populations.

Evaluating, Expanding on Responsive Neurostimulation in Older Adults: Vineet Punia, MD, MS

The neurologist from Cleveland Clinic stressed the potential for responsive neurostimulation in older populations with epilepsy and the need for expanded research.

Improving Access, Standardization of Post-Stroke Smoking Cessation Treatments

Neal Parikh, MD, discussed the inconsistencies with access to treatment regimens aimed at improving smoking cessation in post-stroke patients.

Lower Sodium Oxybate for Excessive Sleepiness, Narcolepsy, and Hypersomnia: Nancy Foldvary-Schaefer, DO, MS

The director of the sleep disorders center at Cleveland Clinic discussed the data on lower sodium oxybate presented at AAN 2021.

Regulatory Outlook for Atogepant in Migraine: Lawrence Severt, MD, PhD

The director at AbbVie discussed the timeline for when a regulatory decision may come for migraine treatment atogepant, and whether additional trials are necessary.

Pimavanserin: Hopes for FDA Approval in Dementia-Related Psychosis

Clive Ballard, MD, the executive dean at the University of Exeter Medical School, discussed the safety and efficacy profile of pimavanserin (Nuplazid; Acadia Pharmaceuticals).

Understanding Disparities in Stroke Care: Sana Somani, MD, MBBS

The vascular neurology fellow at the University of Maryland Medical Center discussed her study’s findings as well as further research she would like to conduct.

Leaving a Nebulous State of Care for Patients With NMOSD: Bruce Cree, MD, PhD

The clinical research director at the UCSF Multiple Sclerosis Center shared some of the takeaways from his research for the clinical community of specialists treating patients with NMOSD.

Better Defining Multiple Sclerosis Categorization: Daniel Ontaneda, MD, PhD

The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the potential of a data-driven approach to classifying patients with MS.

Improving Stroke Discharge Outcomes: Marian LaMonte, MD, MSN, FAAN

The chief of neurology at Ascension Saint Agnes discussed the interventions her team implemented to improve patient-specific stroke discharge instructions.

Clinical Utility of Manual Dexterity Test in MS: Marisa McGinley, DO

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how novel dexterity measurements can improve prognostication of disease progression.

Dosage Finding for IMU-838 in Relapsing MS: Robert Fox, MD

The Vice-Chair for Research at the Cleveland Clinic Neurological Institute discussed his team’s efforts to find the minimally effective dose of IMU-838.

The Issue of Practice Effects on MS Performance Tests: Stephen Rao, PhD, ABPP-Cn

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed his team’s investigations presented at the 2021 AAN Annual Meeting.

Optimizing Treatment in Acute Migraine: Stephanie J. Nahas, MD

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University detailed the ways clinicians can tailor their treatment regimens better.

Remote Screening for Cognitive Impairment: Richard Gershon, PhD

The vice chair for research at the Northwestern University Feinberg School of Medicine discussed the Mobile Toolbox Battery that his team developed.

Gaps in Access to Device-Aided Therapies for Parkinson Disease: Hubert Fernandez, MD

The director of the Center for Neurological Restoration at Cleveland Clinic spoke to how identifying care gaps in Parkinson disease patients is not a niche issue, but part of a bigger problem.

Nipocalimab in Myasthenia Gravis and the Remaining Needs for Patients

Jeffrey Guptill, MD, MS, MHS, associate professor of neurology at neurologist at Duke University, detailed early positive results for nipocalimab in myasthenia gravis and the urgency to provide more treatment options for patients.

Diagnosis Through Teleneurology: Jason Poon, MD

The neurologist at University of Utah discussed the potential of using teleneurology to diagnose neurological conditions.

Data-Driven Categorization of Patients With Multiple Sclerosis: Daniel Ontaneda, MD, PhD

The associate professor of Neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University discussed the findings of his presentation at AAN 2021.

NeuroVoices: Vineet Punia, MD, MS, on Responsive Neurostimulation in Older Adults

The neurologist from Cleveland Clinic discussed his study presented at AAN 2021 involving the use of responsive neurostimulation in older adults with drug-resistant focal epilepsy and further expanding research in this space.

Understanding Fenfluramine’s Impact on Executive Function in Lennox-Gastaut Syndrome

Kim Bishop, PhD, and Arnold Gammaitoni, PharmD, discussed the ways fenfluramine impacts not only seizure frequency, but executive function in individuals with Lennox-Gastaut syndrome.

Advantages of Atogepant in Ever-Growing CGRP Market: Lawrence Severt, MD, PhD

The director at AbbVie highlighted where atogepant stands among the increasing treatment landscape of anti-calcitonin gene-related peptide options within the migraine treatment landscape.

Biomechanical Measures of Upper Extremity Function in MS: Marisa McGinley, DO

The staff neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic spoke to a study using the digital Manual Dexterity Test.

Dyskinesia and OFF Time Disruptions Seen in Most Patients with Parkinson Disease

A survey of more than 500 individuals also found that dyskinesia impacted social interactions and reported that OFF time was isolating.

Lower Sodium Oxybate for Narcolepsy: Nancy Foldvary-Schaefer, DO, MS

The director of the sleep disorders center at Cleveland Clinic discussed her investigations into low-sodium oxybate presented at AAN 2021.